Summary
Bristol Myers Squibb Company (BMY) filed an 8-K on February 2, 2024, to announce its financial results for the fourth quarter and full year of 2023. The filing primarily includes the press release detailing these results (Exhibit 99.1) and a supporting presentation (Exhibit 99.2), both of which were made available on February 2, 2024. These documents provide key financial and operational updates for investors to assess the company's performance. The company is utilizing this 8-K filing to furnish the earnings press release and presentation materials, which contain both GAAP and non-GAAP financial information. Investors are directed to the press release for reconciliations between these measures. The filing itself does not introduce new material events beyond the financial results announcement, but investors should review the furnished exhibits for a comprehensive understanding of BMY's 2023 performance and outlook.
Key Highlights
- 1BMY announced its Q4 and Full Year 2023 financial results on February 2, 2024, via an earnings press release.
- 2The 8-K filing includes the full earnings press release (Exhibit 99.1) and a presentation (Exhibit 99.2) for investors.
- 3The disclosed financial results cover the fourth quarter and the entirety of the fiscal year 2023.
- 4Both GAAP and non-GAAP financial information are referenced in the earnings release and presentation.
- 5Reconciliations for non-GAAP financial measures are available within the furnished earnings press release.
- 6The filing serves as a vehicle to disseminate the company's latest financial performance data and strategic initiatives.